Cosmo Pharmaceuticals N.V. (SWX: COPN)

Market Cap	1.02B
Revenue (ttm)	178.46M
Net Income (ttm)	66.99M
Shares Out	16.05M
EPS (ttm)	4.16
PE Ratio	15.32
Forward PE	9.09
Dividend	1.88 (2.95%)
Ex-Dividend Date	Jul 10, 2024

Volume	11,458
Open	63.50
Previous Close	63.70
Day's Range	63.00 - 64.00
52-Week Range	50.90 - 80.60
Beta	1.25
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 14, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 325
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: COPN

Financial Performance

Financial numbers in EUR